Featured

Hydrogelation preserves whole tumor cells for vaccination

Whole tumor vaccines are appealing as immunotherapies, as they contain the complete range of potential tumor antigens. However, tumor cell inactivation methods often degrade important tumor cell structures and antigens, and the immunogenicity of...

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

To minimize tumor antigen loss and reduce the risk of CD19+ leukemia progression in r/r B-ALL, Arroyo-Ródenas ‍and Falgas et al. developed dual-targeted CD22 CAR T cells secreting an anti-CD19 T cell-...

T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers

Tang, Che et al. utilized semi-supervised learning to stratify potential ICI responders among patients with microsatellite-stable gastric cancers (MSS GCs). The abundance of T-bet+ CD8+ T cells correl...

cGAS mRNA-Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity

Qu, Li et al. generated lipid nanoparticles (LNPs) encapsulating mRNA for cGAS, the innate immune sensor of cytoplasmic dsDNA. Human cGAS was mutated (K187N/L195R) to enhance its activation of the STI...

A dendritic cell-like transition of T cells is associated with spontaneous remission of adult T-cell leukemia-lymphoma

Watanabe et al. analyzed ATL cells and cells infected with the ATL-causing HTLV-1, and identified a small number (<5% on average) of cells expressing DC-associated molecules (CD14, CD1c, CD11b, CD1...

See all for this week

Previous Digests

EPO acts as a tumor’s doping agent to evade immunosurveillance

May 7, 2025

While some biomarkers, such as low tumor mutational burden, have been associated with immune-cold tumors that respond poorly to immune checkpoint blockade (ICB), the mechanisms underlying the immunosuppressive tumor microenvironment (TME) remain largely unknown. Assessing this question, Chiu et...

Treg depletion in brain tumors enhances antitumor responses

April 30, 2025

Glioblastoma and metastases in the brain are difficult to treat with immunotherapy, in part due to poor immune infiltration and a suppressive immune microenvironment, which can be marked by Tregs. Investigating ways of targeting Tregs, Galvez-Cancino et al. investigated...

Prime time: secondary prolonged DC priming boosts high-affinity T cell responses

April 23, 2025

After initial priming through interaction with dendritic cells (DCs), CD8+ T cells disengage and migrate, but little is known about how cytokine signals are transmitted or received by these cells for differentiation during this migration. Jobin, Seetharama, et al...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials